Atenolol nonclinical toxicology

Revision as of 05:17, 5 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Atenolol}} {{CMG}}; {{AE}} {{SS}} ==Nonclinical Toxicology== Chronic studies employing oral atenolol performed in animals have revealed the occurrence of vacuolat...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Atenolol
TENORMIN ® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Atenolol
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Nonclinical Toxicology

Chronic studies employing oral atenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol (starting at 15 mg/kg/day or 7.5 times the maximum recommended human antihypertensive dose11, respectively).[1]



References

  1. "TENORMIN (ATENOLOL) TABLET [ASTRAZENECA PHARMACEUTICALS LP]". Retrieved 5 February 2014.

Template:WikiDoc Sources